Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

Rhythm Pharmaceuticals: Successful Results from Phase 3 Trial with Setmelanotide for Obesity Caused by Genetic BBS

December 29, 2020 0

Rhythm Pharmaceuticals Announces Successful Phase 3 Trial Results for Obesity In November 2020, when the U.S. …

Inovio: Exciting News Published in The Lancet

December 24, 2020 0

Inovio Phase 1 Data of INO-4800 for COVID-19 Peer-reviewed Phase 1 data shows Inovio COVID-19 DNA …

Regenxbio: Advancing its Gene Therapy Pipeline and its Rare Neurodegenerative Disease Platform with Non-Dilutive Capital

December 23, 2020 0

Regenxbio Regenxbio (RGNX) announced that it is selling a portion of its royalty rights from the …

Compugen: More Highlighted News

December 23, 2020 0

Compugen Exclusive License Agreement with AstraZeneca In April 2018 Compugen (CGEN) and AstraZeneca (AZN) entered into …

Gilead Sciences has Good News for Relapsed or Refractory Mantle Cell Lymphoma and More

December 16, 2020 0

Gilead Sciences Company, Kite Pharma, News Kite Pharma, a Gilead Company (GILD), announced that the European Commission …

Intellia Therapeutics: Reinforcing the Promise of Potentially Curing Diseases

December 15, 2020 0

Intellia Therapeutics in the News Intellia Therapeutics (NTLA) presented the first demonstration of physiological protein levels …

Acquisitions that Make Sense

December 14, 2020 0

Acquisitions AstraZeneca Acquires Alexion Pharmaceuticals AstraZeneca (AZN) and Alexion Pharmaceuticals (ALXN) entered into a definitive agreement for …

Our Third Gene-Editing Pick is Joining its Two Sisters on the Road to Great Performances

December 10, 2020 0

CRISPR, Intellia and Editas, Our Gene-Editing Sisters, are Rallying The three CRISPR gene-editing firms that we …

The Biotechnology Industry

December 8, 2020 2

Prohost Letter #443 The Biotechnology Industry The Biotechnology Industry revolutionized the arts of life sciences with …

Why Reata Pharmaceuticals Stock is Down Today. See Also: Important News from Exelixis

December 2, 2020 0

Reata Pharmaceuticals: Why its Stock Price is Down Reata Pharmaceuticals (RETA) announced that it has priced …

Why Intellia Therapeutics’ and Moderna’s Stocks Moved South Yesterday

December 2, 2020 0

Intellia Therapeutics Intellia Therapeutics (NTLA) stock price headed south probably because some robots learned that the …

Regenxbio Announced the First Patient has been Dosed in the Phase I/II trial of RGX-111 for MPS I

December 1, 2020 0

Regenxbio Dosed First Patient with RGX-111 for MPS I Regenxbio (RGNX) has dosed the first patient …

The FDA Approved Rhythm Pharmaceuticals Product IMCIVREE™ for Genetic Obesity due to POMC, PCSK1 or LEPR Deficiency

December 1, 2020 0

Rhythm Pharmaceuticals FDA Approval of IMCIVREE™ for Genetic Obesity At the end of the trading week …

The Latest from Reata Pharmaceuticals. See Also: Prohost Picks that Reached the Moon in Today’s Trading

November 27, 2020 0

Reata Pharmaceuticals We picked Reata Pharmaceuticals (RETA) for investment after confirming that the products the Company …

The US FDA Approved Alnylam’s OXLUMO™ Injection to Lower Urinary Oxalate Levels in Pediatric and Adult Patients with PH1

November 24, 2020 0

Alnylam Announces FDA Approval of OXLUMO™ Injection for PH1 Alnylam (ALNY) announced that the US FDA …

A New COVID-19 Vaccine is Showing Successful Results. See Also: More Details About the Effective COVID-19 Vaccines

November 23, 2020 0

COVID-19 Vaccine Updates Pfizer's (PFE)/BioNTech's (BNTX) and Moderna . . . This content is for paid …

Regeneron Granted FDA Emergency Use Authorization for its COVID-19 Antibody Cocktail Therapy

November 22, 2020 0

Regeneron Pharmaceuticals Receives EUA from the FDA for REGEN-COV2 Regeneron Pharmaceuticals’ (REGN) antibody cocktail therapy casirivimab …

Pfizer and BioNTech Submitted an EUA to the FDA for their COVID-19 Vaccine, BNT162b2

November 21, 2020 0

Pfizer, BioNTech & Moderna When asked whether we heard the news about the submission of the …

Why Gilead Sciences Product Lenacapavir Deserves the FDA Granted Breakthrough Therapy Designation. See Also: Cellectis and Sanofi

November 19, 2020 0

Gilead Sciences News Results from Phase 2/3 CAPELLA trial evaluating Gilead Sciences (GILD) lenacapavir achieved the primary …

PTC Therapeutics’ Many Attractive Achievements and Approvals

November 18, 2020 0

PTC Therapeutics Approvals and Achievements PTC Therapeutics (PTCT) has achieved a lot recently. The latest is …

Exclusive Market Insight

& Scientific analysis

Latest Articlesddd

Rhythm Pharmaceuticals: Successful Results from Phase 3 Trial with Setmelanotide for Obesity Caused by Genetic BBS

Inovio: Exciting News Published in The Lancet

Regenxbio: Advancing its Gene Therapy Pipeline and its Rare Neurodegenerative Disease Platform with Non-Dilutive Capital

Compugen: More Highlighted News

Gilead Sciences has Good News for Relapsed or Refractory Mantle Cell Lymphoma and More

Intellia Therapeutics: Reinforcing the Promise of Potentially Curing Diseases

Acquisitions that Make Sense

Our Third Gene-Editing Pick is Joining its Two Sisters on the Road to Great Performances

The Biotechnology Industry

Why Reata Pharmaceuticals Stock is Down Today. See Also: Important News from Exelixis

Why Intellia Therapeutics’ and Moderna’s Stocks Moved South Yesterday

Regenxbio Announced the First Patient has been Dosed in the Phase I/II trial of RGX-111 for MPS I

The FDA Approved Rhythm Pharmaceuticals Product IMCIVREE™ for Genetic Obesity due to POMC, PCSK1 or LEPR Deficiency

The Latest from Reata Pharmaceuticals. See Also: Prohost Picks that Reached the Moon in Today’s Trading

The US FDA Approved Alnylam’s OXLUMO™ Injection to Lower Urinary Oxalate Levels in Pediatric and Adult Patients with PH1

A New COVID-19 Vaccine is Showing Successful Results. See Also: More Details About the Effective COVID-19 Vaccines

Regeneron Granted FDA Emergency Use Authorization for its COVID-19 Antibody Cocktail Therapy

Pfizer and BioNTech Submitted an EUA to the FDA for their COVID-19 Vaccine, BNT162b2

Why Gilead Sciences Product Lenacapavir Deserves the FDA Granted Breakthrough Therapy Designation. See Also: Cellectis and Sanofi

PTC Therapeutics’ Many Attractive Achievements and Approvals